Our Science
OUR SCIENCE
Congress Presentations
This section includes posters and presentations related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets presented at scientific congresses in the past three years.
AACR-iCML 2024 | Philadelphia, PA
Jun 19 - 22, 2024
Poster
Trial in Progress: Phase 1 Study of ARV-393, a PROteolysis TArgeting Chimera (PROTAC) B-Cell Lymphoma 6 Degrader, in Advanced Non-Hodgkin LymphomaBiennial International LRRK2 Meeting 2024 | Crete, Greece
Jun 18 - 21, 2024
Presentation
Development of Potent, Orally Bioavailable PROTAC® LRRK2 Degrader Molecules as Potential Disease Modifying Therapeutics for NeurodegenerationEHA 2024 | Madrid, Spain
Jun 13 - 16, 2024
Poster
Oral ARV-393 is a BCL6 Degrading PROTAC® Efficacious as a Monotherapy in B-Cell Lymphoma Preclinical CDX and PDX ModelsASCO 2024 | Chicago, IL
May 31 - Jun 4, 2024
Presentation
ARV-766, A PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer: Initial Results of a Phase 1/2 StudyASCO 2024 | Chicago, IL
May 31 - Jun 4, 2024
Poster
TACTIVE-K: Phase 1b/2 Study of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Combination With PF-07220060, a Cyclin-Dependent Kinase 4 Inhibitor, in Estrogen Receptor+/Human Epidermal Growth Factor Receptor 2- Advanced Breast CancerESMO-BC 2024 | Berlin, Germany
May 15 - 17, 2024
Poster
Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, Plus Palbociclib in Estrogen Receptor+/Human Epidermal Growth Factor Receptor 2- Advanced Breast Cancer: Updated Phase 1b Cohort ResultsESMO-BC 2024 | Berlin, Germany
May 15 - 17, 2024
Poster
TACTIVE-K: Phase 1b/2 Study of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Combination With PF-07220060, a Cyclin-Dependent Kinase 4 Inhibitor, in Estrogen Receptor+/Human Epidermal Growth Factor Receptor 2- Advanced Breast CancerAUA 2024 | San Antonio, TX
May 3 - 6, 2024
Poster
ARV-766, a PROTAC Androgen Receptor Degrader, Combined With Abiraterone in Novel Hormonal Agent–Naïve Metastatic Prostate Cancer: Phase 1 Cohort (Part C) of a Phase 1/2 StudyAACR 2024 | San Diego, CA
Apr 5 - 10, 2024